Zoetis (ZTS) has been in focus with several investment firms altering their stakes in the global animal healthcare leader. Notable transactions include a $922,000 investment by North Dallas Bank & Trust Co., Fisher Funds Management LTD, and BLB&B Advisors LLC boosting their positions, while Oversea Chinese Banking Corp Ltd and Montrusco Bolton Investments Inc. reduced their stakes. Nevertheless, the company is attracting investors seeking profitable dividend stocks.
Dividend payments and upcoming earnings projection further strengthen Zoetis’ position.
ZTS secured regulatory nods from EU and Health Canada for its
Lenivia Osteoarthritis Therapy and
Portela and expanded its board with the appointment of Stephanie Tilenius. Yet,
ZTS stock struggled behind market gains. While the firm's Q3 earnings estimates are under the spotlight, the approval of Lenivia has significantly changed its innovation pipeline and recurring revenue outlook. Highlights also indicate Zoetis preparing to launch the world’s first long-acting Anti-NGF therapy for cats by Q4 2025. However, despite Wall Street's bullish views, some views suggest Zoetis to have 'Much bark, little bite'.
Zoetis ZTS News Analytics from Wed, 21 May 2025 07:00:00 GMT to Sat, 01 Nov 2025 11:57:18 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor 2
